Wanqing Chen 1, Rongshou Zheng 2, Peter D Baade 3, Siwei Zhang 4, Hongmei Zeng 4, Freddie Bray 5, Ahmedin Jemal 6, Xue Qin Yu 7 8, Jie He 9
Affiliations Expand
PMID: 26808342 DOI: 10.3322/caac.21338
Free article
Abstract
With increasing incidence and mortality, cancer is the leading cause of death in China and is a major public health problem. Because of China’s massive population (1.37 billion), previous national incidence and mortality estimates have been limited to small samples of the population using data from the 1990s or based on a specific year. With high-quality data from an additional number of population-based registries now available through the National Central Cancer Registry of China, the authors analyzed data from 72 local, population-based cancer registries (2009-2011), representing 6.5% of the population, to estimate the number of new cases and cancer deaths for 2015. Data from 22 registries were used for trend analyses (2000-2011). The results indicated that an estimated 4292,000 new cancer cases and 2814,000 cancer deaths would occur in China in 2015, with lung cancer being the most common incident cancer and the leading cause of cancer death. Stomach, esophageal, and liver cancers were also commonly diagnosed and were identified as leading causes of cancer death. Residents of rural areas had significantly higher age-standardized (Segi population) incidence and mortality rates for all cancers combined than urban residents (213.6 per 100,000 vs 191.5 per 100,000 for incidence; 149.0 per 100,000 vs 109.5 per 100,000 for mortality, respectively). For all cancers combined, the incidence rates were stable during 2000 through 2011 for males (+0.2% per year; P = .1), whereas they increased significantly (+2.2% per year; P < .05) among females. In contrast, the mortality rates since 2006 have decreased significantly for both males (-1.4% per year; P < .05) and females (-1.1% per year; P < .05). Many of the estimated cancer cases and deaths can be prevented through reducing the prevalence of risk factors, while increasing the effectiveness of clinical care delivery, particularly for those living in rural areas and in disadvantaged populations.
Keywords: China; cancer; health disparities; incidence; mortality; survival; trends.
© 2016 American Cancer Society.
PubMed Disclaimer
Similar articles
-
[Analysis of cancer incidence and mortality in elderly population in China, 2013].Zhonghua Zhong Liu Za Zhi. 2017 Jan 23;39(1):60-66. doi: 10.3760/cma.j.issn.0253-3766.2017.01.012.PMID: 28104036 Chinese.
-
[Report of Cancer Incidence and Mortality in China, 2014].Zhonghua Zhong Liu Za Zhi. 2018 Jan 23;40(1):5-13. doi: 10.3760/cma.j.issn.0253-3766.2018.01.002.PMID: 29365411 Chinese.
-
[Incidence and mortality of stomach cancer in China, 2013].Zhonghua Zhong Liu Za Zhi. 2017 Jul 23;39(7):547-552. doi: 10.3760/cma.j.issn.0253-3766.2017.07.015.PMID: 28728305 Chinese.
-
Cancer registration in China and its role in cancer prevention and control.Lancet Oncol. 2020 Jul;21(7):e342-e349. doi: 10.1016/S1470-2045(20)30073-5.PMID: 32615118 Review.
-
Overview and countermeasures of cancer burden in China.Sci China Life Sci. 2023 Nov;66(11):2515-2526. doi: 10.1007/s11427-022-2240-6. Epub 2023 Apr 13.PMID: 37071289 Free PMC article. Review.
Cited by
-
Esophageal cancer risk is influenced by genetically determined blood metabolites.Medicine (Baltimore). 2024 Oct 25;103(43):e40122. doi: 10.1097/MD.0000000000040122.PMID: 39470544 Free PMC article.
-
A systematic review of spatial and temporal epidemiological approaches, focus on lung cancer risk associated with particulate matter.BMC Public Health. 2024 Oct 24;24(1):2945. doi: 10.1186/s12889-024-20431-x.PMID: 39448953 Free PMC article.
-
The Prognostic Value of Non-Predominant Micropapillary Pattern in a Large Cohort of Resected Invasive Lung Adenocarcinoma Measuring ≤3 cm.Front Oncol. 2021 May 7;11:657506. doi: 10.3389/fonc.2021.657506. eCollection 2021.PMID: 34026636 Free PMC article.
-
TP53 mutation and MET amplification in circulating tumor DNA analysis predict disease progression in patients with advanced gastric cancer.PeerJ. 2021 Apr 16;9:e11146. doi: 10.7717/peerj.11146. eCollection 2021.PMID: 33959414 Free PMC article.
-
Targeting POLE2 Creates a Novel Vulnerability in Renal Cell Carcinoma via Modulating Stanniocalcin 1.Front Cell Dev Biol. 2021 Feb 11;9:622344. doi: 10.3389/fcell.2021.622344. eCollection 2021.PMID: 33644060 Free PMC article.


